Preventing Stroke in Patients with Transient Ischemic Attacks

Am Fam Physician. 1999 Nov 15;60(8):2329-2336.

  See related patient information handout on preventing ischemic strokes and treating transient ischemic attacks, written by the authors of this article.

Stroke is the third most common overall cause of death and the leading cause of adult disability in the United States. New therapeutic interventions instituted in the period immediately after a stroke have revolutionized the approach to ischemic cerebrovascular disease. Recognition of a transient ischemic attack provides an opportunity to prevent a subsequent stroke. Specific stroke prevention treatment depends on the cause of the transient ischemic attack, its cerebrovascular localization and the presence of associated coexisting medical problems. Modification of stroke risk factors is the principal therapeutic approach. Antiplatelet agents and anticoagulants have been shown to be effective in reducing the occurrence of stroke in certain populations. Several well-designed studies have recently demonstrated the effectiveness of carotid endarterectomy in preventing strokes related to extracranial carotid artery disease.

Approximately 550,000 new strokes and 150,000 stroke-related deaths occur each year in the United States.1 About 80 percent of strokes are due to ischemic cerebrovascular disease, and the rest are attributable to hemorrhagic causes such as subarachnoid or intracerebral hemorrhage.1 Even though great strides have been made in the identification and treatment of risk factors for stroke and the development of new therapeutic interventions, ischemic stroke continues to be a significant public health problem.

A completed stroke is caused by irreversible brain injury secondary to the interruption of blood flow. In contrast, a transient ischemic attack (TIA) is a temporary focal neurologic deficit caused by the brief interruption of local cerebral blood flow. The prevalence of TIAs ranges from 1.6 to 4.1 percent, depending on gender and age. Stroke occurs in one third of patients who have a TIA.2

The duration of a focal neurologic deficit that leads to cerebral infarction has arbitrarily been determined to be 24 hours or greater. Any focal neurologic deficit that resolves completely within 24 hours is considered a TIA.3 However, a TIA in the carotid territory typically lasts only seven to 10 minutes.3 The diagnosis of a TIA indicates that no irreversible neurologic injury has occurred and provides an excellent opportunity to prevent permanent damage.

Differential Diagnosis and Symptoms

The first step in the evaluation of a patient with possible TIA is to determine if the event in question actually represents a TIA. Table 1 lists conditions that can present with focal neurologic deficit and are sometimes confused with TIAs. These conditions should be ruled out before the diagnosis of TIA is made. Excluding other diagnoses reduces the possibility of inappropriately labeling a patient with the diagnosis of cerebrovascular disease and launching into a course of costly and potentially dangerous diagnostic testing.

TABLE 1

Some Conditions That Can Masquerade as Stroke

Todd's paralysis (postepileptic paralysis)

Hypoglycemia

Complicated migraine

Conversion disorder or malingering

Brain tumor

Drug overdose

Bell's palsy

TABLE 1   Some Conditions That Can Masquerade as Stroke

View Table

TABLE 1

Some Conditions That Can Masquerade as Stroke

Todd's paralysis (postepileptic paralysis)

Hypoglycemia

Complicated migraine

Conversion disorder or malingering

Brain tumor

Drug overdose

Bell's palsy

The symptoms of a TIA depend on the region of the brain that is supplied by the transiently occluded cerebral artery. Precise localization may be difficult because anatomic variations, especially in the arteries that form the circle of Willis, are the rule rather than the exception. The clinical findings most frequently associated with ischemia in various arterial distributions are listed in Table 2. However, other symptoms may occur, and many other clinical stroke syndromes have been described.

TABLE 2

Common Clinical Findings Associated with Ischemia in Various Arterial Distributions

Anterior cerebral artery

Weakness in contralateral leg

Sensory loss in contralateral leg, with or without weakness or numbness in proximal contralateral arm

Middle cerebral artery

Contralateral hemiparesis

Deviation of head and eyes toward side of lesion

Contralateral hemianesthesia

Contralateral hemianopia

Aphasia (if dominant hemisphere is affected)

Unawareness of stroke (if nondominant hemisphere is affected)

Lenticulostriate arteries

Pure motor hemiparesis (lacunar syndrome)

Posterior cerebral artery

Visual field disturbance

Contralateral sensory loss

Amnesia

Vertebrobasilar arteries

Vertigo

Nausea and vomiting

Ataxia

Nystagmus

TABLE 2   Common Clinical Findings Associated with Ischemia in Various Arterial Distributions

View Table

TABLE 2

Common Clinical Findings Associated with Ischemia in Various Arterial Distributions

Anterior cerebral artery

Weakness in contralateral leg

Sensory loss in contralateral leg, with or without weakness or numbness in proximal contralateral arm

Middle cerebral artery

Contralateral hemiparesis

Deviation of head and eyes toward side of lesion

Contralateral hemianesthesia

Contralateral hemianopia

Aphasia (if dominant hemisphere is affected)

Unawareness of stroke (if nondominant hemisphere is affected)

Lenticulostriate arteries

Pure motor hemiparesis (lacunar syndrome)

Posterior cerebral artery

Visual field disturbance

Contralateral sensory loss

Amnesia

Vertebrobasilar arteries

Vertigo

Nausea and vomiting

Ataxia

Nystagmus

If a TIA is recognized, steps can be taken to prevent future ischemic stroke. All TIAs should be promptly investigated because the risk of ischemic stroke is highest soon after a TIA (i.e., 5 percent in the first month).4

Diagnostic Evaluation

INITIAL TESTS

The goals of diagnostic testing are to identify or exclude causes of TIAs that require specific therapy, to assess modifiable risk factors and to determine the prognosis.4  The initial tests recommended for all patients with TIA are listed in Table 3.4

TABLE 3

Initial Evaluation of a Patient with Transient Ischemic Attack

Complete blood cell count with platelet count

Chemistry profile (including cholesterol and glucose levels)

Prothrombin time and activated partial thromboplastin time

Erythrocyte sedimentation rate

Syphilis serology

Electrocardiography

Cranial computed tomography (particularly with hemispheric transient ischemic attack)

Noninvasive arterial imaging (ultrasonography, magnetic resonance angiography)


Information from Guidelines for the management of transient ischemic attacks. Stroke 1994;25:1322.

TABLE 3   Initial Evaluation of a Patient with Transient Ischemic Attack

View Table

TABLE 3

Initial Evaluation of a Patient with Transient Ischemic Attack

Complete blood cell count with platelet count

Chemistry profile (including cholesterol and glucose levels)

Prothrombin time and activated partial thromboplastin time

Erythrocyte sedimentation rate

Syphilis serology

Electrocardiography

Cranial computed tomography (particularly with hemispheric transient ischemic attack)

Noninvasive arterial imaging (ultrasonography, magnetic resonance angiography)


Information from Guidelines for the management of transient ischemic attacks. Stroke 1994;25:1322.

The complete blood count with differential rules out profound anemia, polycythemia, leukocytosis, thrombocytopenia and thrombocytosis as hematologic causes of stroke or as factors that may influence therapy. The chemistry profile demonstrates hypoglycemia that can present with focal neurologic deficits or hyperglycemia that can worsen the outcome after stroke.5

A prothrombin time and an activated partial thromboplastin time are needed to rule out coagulopathies. The erythrocyte sedimentation rate serves as a screening test for autoimmune disorders, and syphilis serology screens for neurosyphilis.

An electrocardiogram (ECG) should be obtained in all patients with TIA or stroke. The ECG is used to detect arrhythmias (e.g., atrial fibrillation) as the cause of ischemia. Computed tomographic (CT) scanning of the head is necessary to rule out intracranial bleeding or tumors. CT evidence of old infarcts, if present, may reveal the vascular distribution of previous ischemic events.

Cerebrovascular ultrasound studies are recommended in all patients with TIA symptoms. These tests are noninvasive but have some limitations. Carotid duplex studies (e.g., Doppler plus B-mode imaging) detect extracranial carotid disease well but may miss intracranial carotid artery disease, vertebral artery disease and complete occlusion.

ADDITIONAL TESTS

One or more of the tests listed in Table 44 may be performed in patients with TIA. Transthoracic and transesophageal echocardiographic examinations do not usually reveal a cause for TIA unless the patient has clinical heart disease. Nonetheless, transthoracic echocardiography is almost always employed in younger patients and in patients for whom no other cause of TIA can be found.4 This examination may also be helpful in identifying atrial thrombus in patients with atrial fibrillation. Transesophageal echocardiography may be useful in confirming suspected atrial appendage thrombus, valvular defects, atrial septal defects, mitral valve vegetation and atrial septal aneurysms.

TABLE 4

Potential Second-Level Evaluation of a Patient with Transient Ischemic Attack*

Transthoracic echocardiography

Transesophageal echocardiography

Transcranial Doppler ultrasonography

Magnetic resonance angiography

Cerebral arteriography

Measurements of antiphospholipid antibodies and other markers for prothrombotic states

Ambulatory electrocardiographic monitoring

Cerebrospinal fluid examination


*—Performed in selected patients as clinically indicated.

Information from Guidelines for the management of transient ischemic at tacks. Stroke 1994;25:1322.

TABLE 4   Potential Second-Level Evaluation of a Patient with Transient Ischemic Attack*

View Table

TABLE 4

Potential Second-Level Evaluation of a Patient with Transient Ischemic Attack*

Transthoracic echocardiography

Transesophageal echocardiography

Transcranial Doppler ultrasonography

Magnetic resonance angiography

Cerebral arteriography

Measurements of antiphospholipid antibodies and other markers for prothrombotic states

Ambulatory electrocardiographic monitoring

Cerebrospinal fluid examination


*—Performed in selected patients as clinically indicated.

Information from Guidelines for the management of transient ischemic at tacks. Stroke 1994;25:1322.

Transcranial Doppler ultrasonography can reveal intracranial stenosis of the trunks of the middle cerebral or posterior cerebral arteries. However, stenotic lesions in smaller branches may be missed.

More recently, magnetic resonance angiography has been used to detect stenosis in extracranial or intracranial cerebral arteries. Arteriography is usually reserved for special situations such as intracranial vasculitis or arterial dissection.4 This study is also performed when cerebrovascular surgery is being considered.4 Although arteriography is expensive and invasive, it is the gold standard for defining occlusive cerebrovascular disease.

Special testing for hypercoagulable states should be reserved for use in patients less than 50 years of age, patients with a history of thrombotic disease and patients in whom no other cause of TIA is found.4 Holter monitoring is recommended for use in patients who had palpitations close in time to the TIA and patients who have an enlarged left atrium.

Lumbar puncture is not routinely recommended as part of the evaluation of patients with TIA. However, this study may be warranted if central nervous system infection is suspected or the presenting symptoms suggest subarachnoid hemorrhage but the CT scan is negative.

Treatment

REDUCTION OF RISK FACTORS

Current theories on the pathogenesis of TIA suggest that effective measures to prevent stroke should also prevent the recurrence of TIA. The initial approach is to modify risk factors that are amenable to treatment (Table 5).631 In this section, emphasis is placed on risk factors that have a definite correlation with the incidence of stroke.

TABLE 5
Summary of National Stroke Association Recommendations for the Prevention of a First Stroke

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

The Stroke Council of the American Heart Association has recommended aggressive treatment of chronic hypertension to maintain the systolic blood pressure below 140 mm Hg and the diastolic blood pressure below 90 mm Hg.4 However, even modest reductions in blood pressure (i.e., 9 mm Hg systolic and 5 mm Hg diastolic) can reduce the relative risk of stroke by about one third.32 Comprehensive recommendations for the treatment of hypertension have been made by the sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.7

Cigarette smoking is associated with an increased risk of stroke. Hence, patients should be strongly encouraged to stop smoking.4

The association of alcohol intake with stroke risk is dose-dependent. Some investigators have described a J-shaped curve for stroke risk, with a slightly increased risk of stroke in patients who are abstinent compared with those who consume moderate amounts of alcohol. Conversely, the risk of stroke is doubled in patients who consume three or more alcohol drinks per day.33 Although absolute statements on alcohol consumption cannot be made based on the available data, heavy drinking should be discouraged.

Atrial fibrillation is one of the strongest independent risk factors for stroke.33 The literature contains a great deal of information on the use of warfarin (Coumadin) or acetylsalicylic acid (aspirin) for stroke prevention in patients with atrial fibrillation.3436 The choice of agent is determined by additional risk factors for stroke and the patient's ability to comply with therapy.3436 Unfortunately, evidence also exists that these treatment options continue to be under-used in up to 75 percent of patients.37

Mildly elevated serum homocysteine levels have been shown to hasten the development of atherosclerosis and thereby increase the risk of ischemic stroke.38 Elevated homocysteine levels can be normalized through the administration of vitamin B6, vitamin B12 or folic acid.39 However, the link between stroke reduction and the administration of these vitamins remains to be proved.

Other potential risk factors for ischemic stroke include hyperlipidemia and diabetes mellitus.13,4046 However, controversy exists regarding the degree of stroke risk associated with these conditions and the action or treatment, if any, that can reduce the risk.

Oral contraceptives may also be associated with an increased risk of stroke. However, several studies have shown that the incidence of stroke is not increased in women who have taken either estrogen or estrogen-progesterone combinations as hormone replacement therapy.44,47

SURGICAL TREATMENT

Once risk factors have been modified, the physician, in collaboration with the patient and family, must decide whether medical or surgical treatment is to be used. The North American Symptomatic Carotid Endarterectomy Trial (NASCET)4,48,49 demonstrated the advantage of endarterectomy over medical management in patients with greater than 70 percent stenosis and neurologic symptoms referrable to the stenosed artery.

Recently published data from NASCET II50 have helped to clarify decision-making in the area of carotid endarterectomies. This trial randomized symptomatic patients (TIA or nondisabling stroke) with carotid stenosis of less than 70 percent to either medical management or carotid endarterectomy. Failure rates for the two treatment groups did not differ significantly in patients with carotid stenosis of less than 50 percent (14.9 percent in the endarterectomy group versus 18.7 percent in the medical management group, P = 0.16). Patients with carotid stenosis of 50 to 69 percent benefited from surgery (failure rate of 15.7 percent in the endarterectomy group versus 22.2 percent in the medical management group, P = 0.045).

The NASCET II investigators have urged physicians to consider several points, such as the surgical risk to the individual patient, the technical skill of the surgeon and the overall complication rate of the institution, when they are contemplating endarterectomy in patients with 50 to 69 percent carotid stenosis.50

Carotid endarterectomy guidelines can be summarized as follows:

  1. Surgery should be considered in symptomatic patients with 70 percent carotid stenosis.48,49

  2. Surgery may be considered in symptomatic patients with carotid stenosis of 50 to 69 percent. The risks and benefits of surgery should be carefully considered in these patients.50

  3. Surgery should not be considered in patients with carotid stenosis of less than 50 percent.50

Some investigators have advocated vertebral artery surgery for patients with vertebrobasilar disease who have continued symptoms despite maximal medical therapy and are good surgical candidates.4 Information on favorable outcomes after vertebral artery surgery for stroke prevention is derived from anecdotal case reports and nonrandomized case series. Hence, this surgical treatment can only be recommended cautiously and in selected patients.4

ANTITHROMBOTIC THERAPY

Some form of stroke prevention therapy must be provided for all patients with TIA. Agents appropriate for this use include aspirin, ticlopidine (Ticlid), clopidogrel (Plavix) and warfarin. When choosing a treatment, the physician should give particular attention to the patient's previous use of prophylactic agents for TIA, if any, and the patient's compliance with these treatments.

Aspirin. Thromboxane A2 is a potent inducer of platelet aggregation. Because aspirin inactivates cyclooxygenase activity for the life of platelets, thromboxane A2 cannot be produced.47 Low and high doses of aspirin appear to reduce thomboxane A2 production. However, prostacyclin, which is thought to have some intrinsic antiplatelet effects, is inhibited in a greater proportion at higher dosages of aspirin.51 The clinical application of this biochemical situation involves finding the appropriate dosage of aspirin for stroke prevention.52,53

Older studies demonstrated benefit from high-dose aspirin therapy (975 to 1,300 mg per day).54,55 Studies such as the Dutch TIA Trial53 and the Swedish Aspirin Low-Dose Trial (SALT)56 have examined the effects of low-dose aspirin therapy.

The randomized, double-blind Dutch study53 compared the use of low-dose aspirin (30 mg per day) and medium-dose aspirin (283 mg per day). No difference between the two treatments was found for the primary outcomes of death from all vascular causes, non-fatal stroke or nonfatal myocardial infarction.

SALT56 compared low-dose aspirin therapy (75 mg per day) with placebo. In this study, treatment with low-dose aspirin decreased the incidence of stroke and death by 18 percent compared with placebo.

No studies have directly compared low-dose, medium-dose and high-dose aspirin therapies for stroke prevention. Thus, the American College of Chest Physicians currently recommends aspirin in a dosage of 50 to 325 mg per day for stroke prevention.11

Ticlopidine. Adenosine diphosphate (ADP) is a nucleotide involved in platelet aggregation and fibrinogen binding to the glycoprotein IIb/IIIa receptor. Ticlopidine prevents these actions, thereby inhibiting platelets for their entire life span.57,58 Studies have shown that ticlopidine (250 mg administered orally twice daily) is more effective than placebo or aspirin in preventing a second thromboembolic stroke.59,60

The adverse events noted in ticlopidine clinical trials were neutropenia, thrombocytopenia, diarrhea, rash, abnormal liver function tests and elevated cholesterol levels.59,60 The manufacturer of ticlopidine recommends close monitoring of complete blood counts with differentials for the first three months of therapy to detect blood dyscrasias.61

Clopidogrel. In early 1998, the U.S. Food and Drug Administration (FDA) labeled clopidogrel for use in the reduction of atherosclerotic events in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease. By irreversibly inhibiting ADP-induced platelet aggregation, clopidogrel prevents clot formation in a similar fashion as ticlopidine.62

In the major trial leading to the FDA labeling of clopidogrel,63 19,185 patients were given either clopidogrel (75 mg per day) or aspirin (325 mg per day). Patients selected for the trial had previous ischemic stroke, myocardial infarction or atherosclerotic peripheral arterial disease. Efficacy was determined by the subsequent occurrence of ischemic stroke, myocardial infarction or vascular death. The incidence of any one of these outcomes was 5.32 percent per year in the clopidogrel-treated group and 5.83 percent per year in the aspirin-treated group, a small but statistically significant difference (P = 0.043).

Clopidogrel appears to have a more promising side effect profile than ticlopidine. In its major clinical trial,63 clopidogrel was more likely to cause rash and diarrhea than aspirin; conversely, aspirin caused nausea, vomiting and gastrointestinal hemorrhage more frequently than clopidogrel. The recommended dosage of clopidogrel is 75 mg per day taken with or without food.64

Warfarin. Few studies have investigated the use of warfarin therapy for stroke prevention outside the setting of atrial fibrillation. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT)65 was halted early because of excess major bleeding complications, particularly intracerebral hemorrhage, in the anticoagulation group. According to investigators in this trial, high-intensity anticoagulation (i.e., International Normalized Ratio [INR] of 3.0 to 4.5) is a customary practice in many European countries. In the United States, an INR range of 2.0 to 3.0 is usually employed for ischemic stroke prevention. SPIRIT demonstrated a clear incremental relationship between hemorrhagic complications and increasing INR, with each 0.5-unit increase in the INR causing the incidence of bleeding to increase by a factor of 1.43.

It is unclear what a comparison of aspirin and warfarin at the standard U.S. INR ranges would show. A single retrospective study66 reviewed outcomes in patients with angiographically identified intracranial artery stenosis who were treated with either warfarin (n = 88) or aspirin (n = 63). A statistically significant difference in the number of recurrent events favored the use of warfarin over aspirin (P <0.01).

A prospective, double-blind randomized study comparing warfarin and aspirin in the prevention of stroke secondary to intracranial stenosis is currently being conducted.

The Authors

MELODY RYAN, PHARM.D., is a clinical pharmacist for the neurology clinic at the University of Kentucky, Lexington. Dr. Ryan holds a dual appointment as assistant professor in the Division of Pharmacy Practice and Science at the College of Pharmacy and the Department of Neurology at the College of Medicine.

GRETA COMBS, M.D., is an assistant professor in the Department of Family Practice at the University of Kentucky College of Medicine. Dr. Combs also serves as curriculum director of the East Kentucky Family Practice Residency at the University of Kentucky Center for Rural Health, Hazard, Ky.

LAROY P. PENIX, M.D., is currently an assistant professor in the Neuroscience Institute and Department of Medicine at Morehouse School of Medicine, Atlanta. Previously he was assistant professor in the Department of Neurology at the University of Kentucky College of Medicine.

Address correspondence to Melody Ryan, Pharm.D., Division of Pharmacy Practice and Science, College of Pharmacy/Department of Neurology, College of Medicine, University of Kentucky, 800 Rose St. (C117), Lexington, KY 40536-0084. Reprints are not available from the authors.

REFERENCES

1. Caplan LR. Introduction and perspective. In: Caplan LR, ed. Stroke: a clinical approach. Boston: Butterworth-Heinemann, 1993:3–22.

2. Heart and stroke statistical update. Dallas: American Heart Association, 1998.

3. Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. N Engl J Med. 1977;296:358–62.

4. Guidelines for the management of transient ischemic attacks. Stroke. 1994;25:1320–35.

5. Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes. Am J Med. 1983;74:540–4.

6. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112–20.

7. The sixth report of the Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–46 [Published erratum in Arch Intern Med. 1998;158:573]

8. Matchar DB, McCrory DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41–53 [Published errata in Ann Intern Med. 1994;121:470 and 1995;122:885]

9. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ. 1998;316:1303–9 [Published erratum in BMJ. 1998; 316:1733]

10. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest. 1998;114[5 suppl]: 611S–33S.

11. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114(5 suppl):683S–98S.

12. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28:1328–428.

13. Bucher HC, Griffith LE, Gyuyatt GH. Effect of HMG-coA reductase inhibitors on stroke. Ann Intern Med. 1998;128:89–95.

14. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. Stroke. 1997;28:946–50.

15. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313–21.

16. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315–20.

17. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Circulation. 1995;91:2274–82.

18. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114(5 suppl):579S–89S.

19. American Diabetes Association: clinical practice recommendations 1998. Diabetes Care. 1998;21 (suppl 1)S1–89.

20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

21. Summary of the second report of the National Cholesterol Education Program (NCEP) Expect Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–23.

22. Woolf SH. Practice guidelines: a new reality in medicine. I. Recent developments. Arch Intern Med. 1990;150:1811–8.

23. The Canadian guide to clinical preventive health care. Ottawa, Ontario: Canada Communication Group Publishing, 1994.

24. Findlay JM, Tucker WS, Ferguson GG, Holness RO, Wallace MC, Wong JH. Guidelines for the use of carotid endarterectomy. CMAJ. 1997;157:653–9.

25. Management of patients with stroke: part II. Management of carotid stenosis and carotid endarterectomy. Scottish Intercollegiate Guidelines Network. Retrieved September 6, 1999, from the World Wide Web: http://pc47.cee.hw.ac.uk/sign/pdf/sign14.pdf.

26. Guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994;121:54–5.

27. Perry JR, Szalai JP, Norris JW. Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis. Arch Neurol. 1997;54:25–8.

28. Guide to clinical preventive services. report of the U.S. Preventive Services Task Force. Baltimore: Williams & Wilkins, 1996:xcii,953.

29. Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh RE, Dempsey RJ, et al. Guidelines for carotid endarterectomy. Circulation. 1998;97:501–9.

30. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health. JAMA. 1995;273:402–7.

31. Physical activity and cardiovascular health. JAMA. 1996;276:241–6.

32. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl. 1994;12:S5–14.

33. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995;333:1392–400.

34. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527–39.

35. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–91.

36. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5–10.

37. Life-saving treatments to prevent stroke underused. AHCPR press release Sept. 7, 1995. Retrieved September 6, 1999, from the World Wide Web: http://www.ahcpr.gov/news/press/stroke.htm.

38. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–8.

39. Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J Nutr. 1996;126(4 suppl):1238S–43S.

40. Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischemic stroke in men. JAMA. 1997;278:2145–50.

41. Crouse JR 3d, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305–10.

42. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

43. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham study. Stroke. 1994;25:40–3.

44. Pederson AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277–83.

45. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among post-menopausal hormone users. Results from a national cohort. Arch Intern Med. 1993;153:73–9.

46. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA. 1987;257:949–52.

47. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–53.

48. Streifler JY, Benavente OR, Harbison JW, Eliasziw M, Hachinski VC, Barnett HJ. Prognostic implications of retinal versus hemispheric TIA in patients with high-grade carotid stenosis: observations from NASCET [Abstract]. Stroke. 1992;26:159.

49. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339:1415–25.

50. Overmyer RH. Treating atherosclerotic disease: current strategies. Formulary. 1998;33(suppl 1):S3–12.

51. Raps EC, Galetta SL. Stroke prevention therapies and management of patient subgroups. Neurology. 1995;45(2 suppl 1):S19–24.

52. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–54.

53. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–6.

54. European Stroke Prevention Study (ESPS). Principal end-points. Lancet. 1987;2(8572):1351–4.

55. Bousser MG, Eschwege E, Haguenau M, Lefaucconier JM, Thibult N, Touboul D, et al. “AICLA”: controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia”. Stroke. 1983;14:5–14.

56. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet. 1991;338:1345–49.

57. Theroux P. Antiplatelet therapy in coronary disease: what agent to use, when, and how? J Thromb Thrombol. 1998;5(suppl 1):S143–50.

58. Schror K. Antiplatelet drugs. A comparative review. Drugs. 1995;50:7–28.

59. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215–20.

60. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–7.

61. Ticlopidine [package insert]. Nutley, N.J.: Roche Laboratories, 1998.

62. Coukel AJ, Markham A. Clopidogrel. Drugs. 1997;54:745–50.

63. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

64. Plavix [pacckage insert]. New York: Sanofi Pharmaceuticals, 1997.

65. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857–65.

66. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45:1488–93.

Each year, members of two different medical faculties develop articles for “Practical Therapeutics.” This article is one in a series coordinated by the Department of Family Practice at the University of Kentucky College of Medicine, Lexington. Guest editors of the series are Bryan F. Yeager, Pharm.D., Thomas Armsey, M.D., and Samuel C. Matheny, M.D., M.P.H.


Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article